Nanologica Ab · OMXSTO:NICA
Nanologica Ab — Q2 2021 Earnings Presentation
18 slides from Nanologica Ab's earnings presentation, Jul 9, 2021
Slide 1: Interim Report Jan - Jun 2021
INTERIM REPORT JAN - JUN 2021 Nanologica AB (publ) Translation
Slide 2: Period in Brief
PERIOD IN BRIEF FINANCIAL OVERVIEW SIGNIFICANT EVENTS IN THE SECOND QUARTER • Thomas Eldered was elected new board member of Nanologica AB Net revenue TSEK 4,497 Net sales for the quarter amounted to TSEK 4,497 (4,321) and for the half-year to • Recruitment of Ulf Ericsson as VP Drug Development as
Slide 3: Large-Scale Production and Toxicity Studies
LARGE-SCALE PRODUCTION AND TOXICITY STUDIES Production of the company's silica for In Drug Development, toxicity studies with our preparative chromatography in large scale inhalation platform NLAB Spiro® are currently proceeds according to plan. Commercial being performed. Results from the first stu
Slide 4: Nanologica in Brief, Operating Income and Result
amounting to TSEK 159,951, which may be the half-yearRAPPORTTILLFÄLLEN KOMMANDE to TSEK -5,464 (-2,074). The activated in the future. Delårsrapport are investments kvartal mainly 1 related 24 to apr advance 2020 NANOLOGICA IN BRIEF Delårsrapport payments related kvartal to volume 2 production 21 aug
Slide 5: Chromatography
CHROMATOGRAPHY order has been placed from the US market and During the autumn, Nanologica intends to the order aims for the customer to evaluate participate in chromatography conferences, with Nanologica's silica for preparative the aim of launching the company's products for chromatography. prepara
Slide 6: Drug Development
strengthen the company's competence in the As part of the partner project in plant protection, field, Ulf Ericsson has been recruited as VP Drug which was initiated in 2017, Nanologica was in Development. The role includes leading the the autumn of 2020 commissioned to formulate development and comm
Slide 7: Employees and Organization, Patents, Partnerships
KOMMANDE RAPPORTTILLFÄLLEN thalidomide for local lung delivery for the projects in the Drug Development business area Delårsrapport kvartal 1 24 apr 2020 EMPLOYEES AND ORGANIZATION treatment of IPF (idiopathic pulmonary fibrosis). are expected to focus primarily on inhaled drugs IMPACT OF COVID-19 D
Slide 8: The Share and Owners, Share-Based Incentive Programs
KOMMANDE RAPPORTTILLFÄLLEN number of shares in the company amounted to 800,000. Based on the existing number of shares Delårsrapport they are also kvartal kept1 available. 24 apr 2020a Through THE SHARE AND OWNERS 27,794,480 and the market capitalization was in, the dilution will be a maximum of Del
Slide 9: Financial Statements and Notes
FINANCIAL STATEMENTS AND NOTES Statement of comprehensive income 10 Consolidated financial position 10 Consolidated statement of changes in equity 11 Consolidated statement of cashflow 11 Key figures 12 Income statement parent company 12 Financial position, parent company 13 Changes in equity, paren
Slide 10: Nanologica Interim Report Jan-Jun 2021
Nanologica Interim Report Jan-Jun 2021 10
Slide 11: Nanologica Interim Report Jan-Jun 2021
Nanologica Interim Report Jan-Jun 2021 11
Slide 12: Definitions Key Figures
*DEFINITIONS KEY FIGURES Earnings per share = Earnings after tax divided by the average number of shares for the period Equity ratio = Equity on the closing day divided by the balance sheet total Equity per share = Equity on the closing day divided by the number of shares on the closing day Nanologi
Slide 13: Nanologica Interim Report Jan-Jun 2021
Nanologica Interim Report Jan-Jun 2021 13
Slide 14: Nanologica Interim Report Jan-Jun 2021
Nanologica Interim Report Jan-Jun 2021 14
Slide 15: Notes
NOTES NOTE 1 GENERAL INFORMATION This report covers the Swedish parent company Nanologica AB (publ), corporate registration number 556664-5023, and its subsidiaries. The parent company is a limited liability company with its registered office in Stockholm, Sweden. The address of the main office is F
Slide 16: Note 4 Transition to IFRS
NOTE 4 TRANSITION TO IFRS Nanologica AB has previously applied the Swedish Annual Accounts Act and BFNAR 2012: 1 Annual Report and Consolidated Accounts ("K3"). As of 1 January 2020, Nanologica AB prepares its consolidated financial statements in accordance with EU approved International Financial R
Slide 17: Note B: Valuation of Financial Instruments at Fair Value
• Note B: Valuation of financial instruments at fair value. a. At the time of sale during the third quarter, 2018, compensation was received from the customer in the form of the customer's own shares (listed on the market). According to RFR 2, the shares shall be considered part of the transaction (
Slide 18: Nanologica AB contact details
Nanologica AB Forskargatan 20G SE-151 36 Södertälje Sweden +46 8 410 749 49 info@nanologica.com www.nanologica.com